Multiple Sclerosis

Primary Care - Clinics in Office Practice

Volumn 42, Issue 2, 2015, Pages 159-175

  Files, Daniel Kane ^a   Jausurawong, Tani ^a   Katrajian, Ruba ^a   Danoff, Robert ^a  

^a Family Medicine Residency   (United States)

Author keywords

Epstein Barr virus; Latitude; Multiple sclerosis; Vitamin D

Indexed keywords

AMITRIPTYLINE; BACLOFEN; BETA1A INTERFERON; CARBAMAZEPINE; CYCLOBENZAPRINE; DANTROLENE; DULOXETINE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GABAPENTIN; GADOLINIUM; GLATIRAMER; HYOSCYAMINE; INTERFERON BETA SERINE; METAXALONE; MITOXANTRONE; NATALIZUMAB; NORTRIPTYLINE; OXYBUTYNIN; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SOLIFENACIN; TADALAFIL; TERIFLUNOMIDE; TIZANIDINE; TOLTERODINE; UNINDEXED DRUG; VARDENAFIL; VITAMIN D; ANTIRHEUMATIC AGENT;

ACUPUNCTURE; AUTOIMMUNE DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DISABILITY SEVERITY; EPSTEIN BARR VIRUS; ERECTILE DYSFUNCTION; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FUNCTIONAL SYSTEM SCORE; HUMAN; LATITUDE; MANIPULATIVE MEDICINE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHYSICAL EXAMINATION; PHYSICAL INACTIVITY; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SEASONAL VARIATION; SMOKING; SPASTICITY; SUBSTANCE ABUSE; SUN EXPOSURE; URINARY URGENCY; WEAKNESS; BLOOD; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE COURSE; GENETIC PREDISPOSITION; PRIMARY HEALTH CARE; PROCEDURES; RISK FACTOR;

ANTIRHEUMATIC AGENTS; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; DISABILITY EVALUATION; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE SCLEROSIS; PRIMARY HEALTH CARE; QUALITY OF LIFE; RISK FACTORS; VITAMIN D;

EID: 84929506548     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2015.01.007     Document Type: Review

References (36)

1. MS Overview. What is multiple sclerosis? Multiple Sclerosis Association of America; Web. 01 Mar 2015. Available at: http://mymsaa.org/about-ms/overview/#WhoGetsMS.
2. Koch-Henriksen N., Sorensen P.S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010, 9:520-532.
3. Scalfari A., Knappertz V., Cutter G., et al. Mortality in patients with multiple sclerosis. Neurology 2013, 81:184-192.
4. Olek M.J. Epidemiology and clinical features of multiple sclerosis in adults 2013, UpToDate, Web. 26 Jan. 2014. Available at:. http://www.uptodate.com/contents/pathogenesis-and-epidemiology-of-multiple-sclerosis?source=see_link.
5. Ramagopalan S.V., Sadovnick A.D. Epidemiology of multiple sclerosis. Neurol Clin 2011, 29:207-217.
6. Ebers G.C. Environmental factors and multiple sclerosis. Lancet Neurol 2008, 7:268-277.
7. Ascherio A., Munger K.L., Simon K.C. Vitamin D and multiple sclerosis. Lancet Neurol 2010, 9:599-612.
8. HLA-DRB1 - major histocompatibility complex, class II, DR beta 1 2014, U.S. National Library of Medicine, Bethesda (MD), Web. 26 Jan. 2014. Available at:. http://ghr.nlm.nih.gov/gene=HLA-DRB1.
9. Simpson S., Blizzard L., Otahal P., et al. Latitude is significantly associated with the prevalence of Multiple Sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011, 82:1132-1141.
10. Walsh N. Autoimmunity and a wily virus: is there a link? Autoimmunity and a wily virus: is there a link?. MedPage Today 2014, Web. 26 Jan. 2014.
11. Hernan M.A., Olek M.J., Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001, 154:69-74.
12. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955.
13. Nylander A., Hafler D.A. Multiple sclerosis. J Clin Invest 2012, 122:1180-1188.
14. Popescu B.F., Pirko I., Lucchinetti C.F. Pathology of multiple sclerosis: where do we stand?. Continuum (Minneap Minn) 2013, 19:901-921.
15. Goodin D.S. Multiple sclerosis and other demyelinating diseases. Harrison's principles of internal medicine 2012, Chapter 380, McGraw-Hill, New York, Available at:, Accessed January 3, 2014. http://www.accessmedicine.com/content.aspx?aID=9147780, 18th edition. D.L. Longo, A.S. Fauci, D.L. Kasper (Eds.).
16. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability scale. Neurology 1983, 33:1444-1452.
17. Marsha TL. Multiple Sclerosis Centers of Excellence. Kurtzke Expanded Disability Status Scale. Veterans Affairs Puget Sound Health Care System - Seattle, Dec 2009. Web. 01 Mar 2014.
18. Jelinek G.A. Kurtzke EDSS scale. Overcoming multiple sclerosis 2013, Overcoming MS, Web. 1 Jan. 2014.
19. Marcus J.F., Waubant E.L. Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist 2012, 3(2):65-80.
20. Ali E.N., Buckle G.J. Neuroimaging in multiple sclerosis. Neurol Clin 2009, 27(1):203-219.
21. Palace J. Making the diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001, 71:ii3-ii8. Available at:. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1765569/pdf/v071p00ii3.pdf.
22. Matloff J. Multiple sclerosis. Principles and practice of hospital medicine 2012, Chapter 213, McGraw-Hill, New York, Available at:, Accessed January 3, 2014. http://www.accessmedicine.com/content.aspx?aID=56211606, J. Matloff, D.D. Dressler, D.J. Brotman (Eds.).
23. Miller D.H., Weinshenker B.G., Filippi M., et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008, 14:1157-1174.
24. Marrie R.A., Hanwell H. General health issues in multiple sclerosis: comorbidities, secondary conditions, and health behaviors. Continuum (Minneap Minn) 2013, 19(4):1046-1057.
25. Blanco-Kelly F., Matesanz F., Alcina A., et al. CD40: novel association with Crohn's disease and replication in multiple sclerosis susceptibility. PLoS One 2010, 5:e11520.
26. Eisenbarth G.S. Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 2010, 59:759-774.
27. Rubin S.M. Management of multiple sclerosis: an overview. Dis Mon 2013, 59(7):253-260.
28. Mullarkey C. FDA approves new treatment regimen for multiple sclerosis. Consultant 360; 2/11/14.
29. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354(9):899-910.
30. Bloomgren G., Richman S., Hotermans C., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012, 366(20):1870-1880.
31. Ransohoff R. Natalizumab for multiple sclerosis. N Engl J Med 2007, 356(25):2622-2629.
32. Pelletier D., Hafler D.A. Fingolimod for multiple sclerosis. N Engl J Med 2012, 366(4):339-347.
33. O'Connor P., Wolinsky J.S., Confavreux C., et al. Randomized trial of teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011, 365(14):1293-1303.
34. Fox R.J., Miller D.H., Phillips J.T., et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012, 367(12):1087-1097.
35. Calabresi P. Diagnosis and management of multiple sclerosis. Am Fam Physician 2004, 70(10):1935-1944.
36. Wening J., Ford J., Jouett L.D. Orthotics and FES for maintenance of walking in patients with MS. Dis Mon 2013, 59(8):284-289.